Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LCTX Stock Forecast 2026-2027
$1.21
Current Price
$301.65M
Market Cap
Buy 6
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to LCTX Price Targets
+643.8%
To High Target of $9.00
+271.9%
To Median Target of $4.50
+147.9%
To Low Target of $3.00
LCTX Price Momentum
0.0%
1 Week Change
-11.7%
1 Month Change
+68.1%
1 Year Change
-27.5%
Year-to-Date Change
-42.1%
From 52W High of $2.09
+80.6%
From 52W Low of $0.67
📊 TOP ANALYST CALLS
Did LCTX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Lineage is one of their latest high-conviction picks.
Latest LCTX Stock Price Targets & Analyst Predictions
Based on our analysis of 1 Wall Street analyst, LCTX has a bullish consensus with a median price target of $4.50 (ranging from $3.00 to $9.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $1.21, the median forecast implies a 271.9% upside. This outlook is supported by 6 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LCTX Analyst Ratings
6
Buy
1
Hold
0
Sell
LCTX Price Target Range
Low
$3.00
Average
$4.50
High
$9.00
Current: $1.21
Latest LCTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LCTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 4, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Apr 28, 2026 | Canaccord Genuity | Buy | Initiates | $N/A | |
| Mar 25, 2026 | B. Riley Securities | Buy | Maintains | $N/A | |
| Mar 24, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 6, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Feb 9, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Nov 25, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Nov 24, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Aug 27, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Aug 14, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Aug 5, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Jun 23, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Jun 23, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 14, 2025 | B. Riley Securities | Buy | Maintains | $N/A | |
| Mar 11, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Mar 11, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 11, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 11, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Jan 31, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 10, 2025 | Maxim Group | Buy | Maintains | $N/A |
Lineage Cell Therapeutics Inc. (LCTX) Competitors
The following stocks are similar to Lineage based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Lineage Cell Therapeutics Inc. (LCTX) Financial Data
Lineage Cell Therapeutics Inc. has a market capitalization of $301.65M with a P/E ratio of -4.4x. The company generates $14.78M in trailing twelve-month revenue with a 99.0% profit margin.
Revenue growth is +14.8% quarter-over-quarter, while maintaining an operating margin of -440.2% and return on equity of -98.2%.
Valuation Metrics
Market Cap
$301.65M
Enterprise Value
$249.48M
P/E Ratio
-4.4x
PEG Ratio
-13.4x
Price/Sales
20.4x
Growth & Margins
Revenue Growth (YoY)
+14.8%
Gross Margin
+100.0%
Operating Margin
-440.2%
Net Margin
+99.0%
EPS Growth
+14.8%
Financial Health
Cash/Price Ratio
+17.7%
Current Ratio
6.9x
Debt/Equity
4.5x
ROE
-98.2%
ROA
-12.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Lineage Cell Therapeutics Inc. (LCTX) Business Model
About Lineage Cell Therapeutics Inc.
What They Do
Develops cell therapies for neurological and ophthalmic conditions.
Business Model
The company operates as a clinical-stage biotechnology firm, utilizing a proprietary cell-based technology platform to design and manufacture specialized human cells. It generates revenue through collaborations with larger industry partners and potentially through the commercialization of its innovative therapies targeting serious conditions.
Additional Information
Lineage Cell Therapeutics is based in Carlsbad, California, and has a diverse pipeline that includes treatments for dry age-related macular degeneration, spinal cord injury, and oncology applications. Founded in 1990, the company aims to advance its therapies toward broader clinical use.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
70
CEO
Mr. Brian M. Culley M.A., M.B.A.
Country
United States
IPO Year
1992
Website
www.lineagecell.comLineage Cell Therapeutics Inc. (LCTX) Latest News & Analysis
Latest News
Quick Summary
Lineage Cell Therapeutics (LCTX) reported Q1 2026 results, highlighting advancements in its cell therapy pipeline, including the OpRegen program and the new COR1 corneal cell initiative.
Why It Matters
Lineage Cell Therapeutics' progress in cell therapies and new programs may enhance growth potential, impacting stock performance and attracting investor interest in biotechnology.
Source: MarketBeat
Market Sentiment:
Positive
Quick Summary
Lineage Cell Therapeutics, Inc. (LCTX) held its Q1 2026 earnings call, discussing financial performance and strategic developments. Further details will be available in the transcript.
Why It Matters
The Q1 2026 earnings call provides insights into Lineage Cell Therapeutics’ financial performance and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
27 days ago
Quick Summary
Lineage Cell Therapeutics (NYSE: LCTX) reported its Q1 2026 financial results and will host a conference call today at 4:30 PM ET for discussion and business updates.
Why It Matters
Lineage Cell Therapeutics' quarterly results and conference call may impact stock performance and investor sentiment, especially regarding its clinical advancements and financial health.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Lineage Cell (LCTX) reported a quarterly loss of $0.03 per share, exceeding the Zacks Consensus Estimate of a $0.02 loss, and compared to a loss of $0.02 per share from the previous year.
Why It Matters
Lineage Cell's larger-than-expected quarterly loss may signal ongoing financial challenges, potentially impacting investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Lineage Cell Therapeutics (NYSE: LCTX) will report Q1 2026 financial results on May 12, 2026, post-market, followed by a conference call at 4:30 p.m. Eastern Time.
Why It Matters
Lineage Cell Therapeutics' upcoming financial report and conference call will provide insights into its performance and development progress, influencing investor sentiment and stock valuation.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Lineage Cell Therapeutics announced 36-month results from a Phase 1/2a study of RG6501 (OpRegen) for geographic atrophy due to age-related macular degeneration.
Why It Matters
The 36-month results from Lineage Cell Therapeutics' clinical study on RG6501 could significantly impact its stock value and investor sentiment, indicating potential for future revenue and market growth.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About LCTX Stock
What is Lineage Cell Therapeutics Inc.'s (LCTX) stock forecast for 2026?
Based on our analysis of 1 Wall Street analysts, Lineage Cell Therapeutics Inc. (LCTX) has a median price target of $4.50. The highest price target is $9.00 and the lowest is $3.00.
Is LCTX stock a good investment in 2026?
According to current analyst ratings, LCTX has 6 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.21. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LCTX stock?
Wall Street analysts predict LCTX stock could reach $4.50 in the next 12 months. This represents a 271.9% increase from the current price of $1.21. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Lineage Cell Therapeutics Inc.'s business model?
The company operates as a clinical-stage biotechnology firm, utilizing a proprietary cell-based technology platform to design and manufacture specialized human cells. It generates revenue through collaborations with larger industry partners and potentially through the commercialization of its innovative therapies targeting serious conditions.
What is the highest forecasted price for LCTX Lineage Cell Therapeutics Inc.?
The highest price target for LCTX is $9.00 from at , which represents a 643.8% increase from the current price of $1.21.
What is the lowest forecasted price for LCTX Lineage Cell Therapeutics Inc.?
The lowest price target for LCTX is $3.00 from at , which represents a 147.9% increase from the current price of $1.21.
What is the overall LCTX consensus from analysts for Lineage Cell Therapeutics Inc.?
The overall analyst consensus for LCTX is bullish. Out of 1 Wall Street analysts, 6 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $4.50.
How accurate are LCTX stock price projections?
Stock price projections, including those for Lineage Cell Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 9, 2026 3:10 AM UTC